Obseva (OBSV) Getting Somewhat Positive Press Coverage, Study Shows
Media stories about Obseva (NASDAQ:OBSV) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Obseva earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.1985097670112 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- ObsEva SA – ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial … (romandie.com)
- ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018 (finance.yahoo.com)
- Leerink Swann Weighs in on Obseva SA’s FY2020 Earnings (OBSV) (americanbankingnews.com)
- ObsEva SA – ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting (romandie.com)
- Wired News – ObsEva Released Positive Top-line Results from IMPLANT2 Phase-3 Clinical Trial Evaluating Nolasiban in IVF (finance.yahoo.com)
Several analysts have recently commented on OBSV shares. HC Wainwright set a $25.00 price target on Obseva and gave the company a “buy” rating in a report on Wednesday, November 29th. BMO Capital Markets reissued a “buy” rating and issued a $24.00 price target on shares of Obseva in a report on Tuesday, February 27th. Credit Suisse Group reissued a “buy” rating and issued a $18.00 price target (up from $16.00) on shares of Obseva in a report on Tuesday, February 27th. Zacks Investment Research cut Obseva from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Finally, Leerink Swann raised their price target on Obseva from $17.00 to $18.00 and gave the company an “outperform” rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Obseva has a consensus rating of “Buy” and an average price target of $19.67.
TRADEMARK VIOLATION WARNING: “Obseva (OBSV) Getting Somewhat Positive Press Coverage, Study Shows” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.dailypolitical.com/2018/03/03/obseva-obsv-getting-somewhat-positive-press-coverage-study-shows.html.
Obseva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.